Description
60mg is supplied as four separate 15mg vials to enhance stability. Reconstituting each vial only when needed helps maintain purity and allows for easier, more precise volume preparation.
Tirzepatide is a once-weekly subcutaneous injection. As a dual receptor agonist, it stimulates both GLP-1 and GIP receptors, slowing digestion and reducing appetite.
Key Information About Tirzepatide:
-
- Mechanism: It mimics GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) hormones to manage blood sugar and increase satiety.
- Administration: It is a synthetic peptide injected once a week.
- Weight Loss Efficacy:
Studies showed significant weight reduction, with higher doses (15 mg) leading to approximately 15% to 21% body weight loss in 72 weeks.
- Dosage: Typical dosage starts low and increases, with maximum doses often being 15 mg weekly.
- Side Effects: Nausea, diarrhea, vomiting, constipation, and stomach pain are common, particularly during dose increases.
- Contraindications: It is not for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Common Food and Drink to Avoid:
-
To mitigate side effects, it is recommended to avoid:
-
Fried, greasy, or high-fat foods.
-
Sugary foods and drinks.
-
Refined carbohydrates.
-
Excessive alcohol.
Patients reach and maintain lower HbA1c and weight levels.
Disclaimer: This information is for educational purposes based on research studies and does not constitute medical advice. Consult a healthcare provider before starting any peptide therapy.
Reviews
There are no reviews yet.